(19)
(11) EP 1 922 061 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.09.2010 Bulletin 2010/36

(45) Mention of the grant of the patent:
17.12.2008 Bulletin 2008/51

(21) Application number: 06761981.7

(22) Date of filing: 07.06.2006
(51) International Patent Classification (IPC): 
A61K 9/16(2006.01)
 A61K 31/4439(2006.01)
(86) International application number:
PCT/EP2006/005423
(87) International publication number:
WO 2006/133835 (21.12.2006 Gazette 2006/51)

(54)

ORAL SOLID PHARMACEUTICAL FORMULATION OF THE TUBULIN INHIBITOR INDIBULIN

FESTE ORALE DARREICHUNGSFORM DES TUBULINHEMMSTOFFS INDIBULIN

FORMULATION SOLIDE PHARMACEUTIQUE ORALE DU COMPOSE INDIBULINE INHIBITEUR DE LA TUBULINE

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
Designated Extension States:
HR

(30) Priority: 14.06.2005 US 151459

(43) Date of publication of application:
21.05.2008 Bulletin 2008/21

(73) Proprietor: ZIOPHARM ONCOLOGY, INC.
Boston, MA 02129 (US)

(72) Inventors:
  • ROESSLER, Berthold
    33790 Halle (DE)
  • RAAB, Gerhard
    63549 Ronneburg (DE)
  • REISSMANN, Thomas
    21335 Lueneburg (DE)

(74) Representative: Hock, Joachim 
Müller-Boré & Partner Grafinger Strasse 2
81671 München
81671 München (DE)


(56) References cited: : 
WO-A-03/037861
WO-A1-2006/002887
 WO-A-2006/052712
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).